Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Change in Cash: 2020-2025

Historic Change in Cash for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -$5.8 million.

  • Insight Molecular Diagnostics' Change in Cash rose 1.97% to -$5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.1 million, marking a year-over-year increase of 245.36%. This contributed to the annual value of -$796,000 for FY2024, which is 93.41% up from last year.
  • Insight Molecular Diagnostics' Change in Cash amounted to -$5.8 million in Q3 2025, which was up 14.31% from -$6.7 million recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Change in Cash peaked at $51.8 million during Q1 2021, and registered a low of -$15.2 million during Q1 2022.
  • Over the past 3 years, Insight Molecular Diagnostics' median Change in Cash value was -$3.9 million (recorded in 2024), while the average stood at -$272,091.
  • Data for Insight Molecular Diagnostics' Change in Cash shows a peak YoY increase of 1,041.85% (in 2021) and a maximum YoY decrease of 5,779.45% (in 2021) over the last 5 years.
  • Insight Molecular Diagnostics' Change in Cash (Quarterly) stood at -$7.7 million in 2021, then slumped by 36.39% to -$10.6 million in 2022, then spiked by 58.76% to -$4.4 million in 2023, then skyrocketed by 221.19% to $5.3 million in 2024, then grew by 1.97% to -$5.8 million in 2025.
  • Its Change in Cash stands at -$5.8 million for Q3 2025, versus -$6.7 million for Q2 2025 and $22.4 million for Q1 2025.